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to be 97.4% by Botzenhardt and colleagues4 and 87.1%
at 10 years by Riess and colleagues.2 In the review by
Riess and colleagues, there was no structural valvular de-
terioration at 10 years in patients aged more than 65
years.2
Improved valve durability in patients aged more than 65
years in reported studies2,3 was not seen in our patients.
All 4 patients were aged more than 68 years at the time of
implant, and all were aged 70 years or more at the time of
the redo operation.
Patient–prosthesis mismatch was excluded as a cause of
early stenosis because the indexed effective orifice area
was greater than 0.75 cm2/m2 in all 4 patients. Explanted
valves were examined by a pathologist at the Washington
University School of Medicine and by a pathologist after re-
turn of the valves to Medtronic Inc, and no cause for the ste-
nosis could be determined in any case. The cause of early
valvular stenosis, whether it is related to patient factors or
valve factors, remains unclear.
CONCLUSIONS
Continued close and long-term follow-up of patients re-
ceiving the Medtronic Mosaic porcine valve is imperative.
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TABLE 1. Clinical data in 4 patients in whom early (3–44 months) valvular stenosis developed
Patient
Year of
implant
Implant
position
and size
Indexed effective
orifice area
(EOA/BSA in cm2/m2)
Indication for
explantation
(aortic valve
gradients in mm Hg)
Months
implanted
Age at redo
operation (y) Operative findings
A 2002 Aortic, 23 mm 1.51/1.81 ¼ 0.83 Aortic stenosis (AVA 1.0
cm2), peak 44, mean 26
44 76 Thickened leaflets,
small perforation 1 leaflet
B 2003 Aortic, 23 mm 1.51/1.99 ¼ 0.76 Aortic stenosis (AVA 0.7
cm2), peak 88, mean 45
14 74 Thickened leaflets
(Figure 1, A)
C 2004 Aortic, 23 mm 1.51/1.83 ¼ 0.83 Aortic stenosis (AVA 0.7
cm2), peak 100,
mean 60
19 70 Thickened leaflets,
pannus
D 2007 Aortic, 25 mm 1.69/1.90 ¼ 0.89 Aortic stenosis, peak 65,
mean 42
3 73 Thickened leaflets, pannus
(Figure 1, B)
AVA, Aortic valve area; BSA, body surface area; EOA, effective orifice area.
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transplantation (OHT) is of concern owing to its correlation
with right ventricular dysfunction and mortality.1
Studies show that the bicaval anastomosis technique
decreases the incidence TR when compared with biatrial
techniques.2 More recent studies show that modified surgi-
cal techniques, such as tricuspid valve annuloplasty or
a modified inferior vena cava anastomosis, may alleviate
moderate and severe TR after transplantation.3,4
This study examines the long-term natural history of TR
after OHT.rdiovascular Surgery c Volume 137, Number 6 1557
Brief CommunicationsPATIENTS AND METHODS
From January 1997 to December 2005, 670 consecutive adults under-
went heart transplantation with the bicaval anastomosis technique. The
mean age was 53.4  13.2 years (range, 18.3–70.5). The male recipients
comprised 69.4% of the cohort. The etiology of cardiomyopathy before
OHT was idiopathic dilated (45%), ischemic (39%), retransplant (6%),
or other (10%). The mean ischemic time was 212.8  71.4 minutes.
Donor hearts were flushed with a cold University of Wisconsin solution
and reperfused with leukocyte-depleted blood.
Both routine echocardiogram reports and those monitoring clinical
changes were retrospectively reviewed, and TR was considered present if
TR was documented as greater than mild on any report. All recipients had
at least a 1-year follow-up. A Kaplan–Meier model was used to measure
freedom from TR (SPSS version 14 software; SPSS, Inc, Chicago, Ill),
and to account for competing outcomes (either TR>mild or death) all
recipients dying without TR were considered to have a follow-up time equal
to survival time. A Kaplan–Meier curve was used to measure the survival
difference between the TR  mild and TR>mild groups, and a log–rank
test was used to compare the two groups. For both Kaplan–Meier analyses,
the length of follow-up was considered reliable so long as there were more
than 35 recipients remaining at risk. The duration of follow-up was 9 years
for the entire cohort and 5 years when comparing survival between TR 
mild and TR>mild groups. Cox regression analysis was performed to
determine TR’s correlation with survival, age, and ischemic time.
The research protocol was presented to the institutional review board,
and the requirement for informed consent was waived.
RESULTS
Actuarial freedom from TR in the 670 patients was 78%
at 9 years (Figure 1). The risk was highest in the first year
after transplantation, with a lower but steady occurrence
thereafter.
A total of 102 (14.9%) recipients had TR at some point
in their follow-up. When examining survival between the
TR  mild and TR>mild groups, the largest difference oc-
curred at 10 months (90.1% vs 75.7%, respectively). Five-
FIGURE 1. Actuarial freedom from TR in the 670 patients was 78% at
9 years. TR, Tricuspid regurgitation.1558 The Journal of Thoracic and Cardiovascular Suryear survival was 78.3% for those with TR  mild and
65.3% for those with TR>mild (Figure 2).
Regression analysis confirmed that TR was predictive
of mortality, and that TR was not correlated with ischemic
time or recipient age (P¼ .001, .088, and .494, respectively).
DISCUSSION
By examining the natural history of TR after OHT with
bicaval anastomosis, our study assessed the effectiveness
of the bicaval technique.
The study by Anderson and associates1 examined TR af-
ter OHT with biatrial and bicaval techniques in 130 patients
and determined that intraoperative TR negatively affects
survival. The study by Aziz and coworkers,2 following
201 patients for 4 years, found that the incidence of moder-
ate-to-severe TR was 17% beyond 1-year follow-up. Our
results supported these observations using a much larger co-
hort and a longer follow-up time. We also found that the in-
cidence of TR was highest in the first year and that there
continued to be a risk of new TR beyond that, although
the late risk may have been aggravated by repeated biopsies.5
Bicaval anastomosis decreases the occurrence of TR when
compared with previously standard OHT techniques; how-
ever, the actuarial freedom from TR at 9 years (78%) sug-
gests the technique’s imperfection for maintaining proper
tricuspid valve function. The largest difference between
the TR  mild and TR>mild survival curves was observed
10 months after OHT, and afterward the two curves contin-
ued in parallel. The initially large survival difference
between the two groups is consistent with recipients’ early
postoperative vulnerability, during which risk factors such
FIGURE 2. Five-year survival was 78.3% for those with TR  mild and
65.3% for those with TR>mild. TR, Tricuspid regurgitation.gery c June 2009
Brief Communicationsas allograft dysfunction, pulmonary hypertension, rejection,
and infection can all wear down right ventricle reserve.
Bicaval anastomosis provides a durable but imperfect re-
sult for tricuspid valve function, and the addition of TR as
a risk factor increases risk for mortality in the first year after
transplantation. The results support prior studies that have
not gained universal acceptance, such as those proposing
annuloplasty in conjunction with the bicaval technique or
a modified inferior vena cava anastomosis facilitating annu-
loplasty.3,4 Improving current surgical implantation prac-
tices has the potential to alleviate tricuspid insufficiency
after heart transplantation, thus improving recipients’ sur-
vival outcomes.The Journal of Thoracic and CReferences
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